Pulmatrix (NASDAQ:PULM) Receives Sell (E+) Rating from Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Friday,Weiss Ratings reports.

Pulmatrix Price Performance

Shares of PULM opened at $4.93 on Friday. The firm has a 50-day moving average of $4.85 and a 200-day moving average of $5.94. Pulmatrix has a one year low of $2.00 and a one year high of $10.40. The company has a market cap of $17.99 million, a PE ratio of -2.90 and a beta of 1.64.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings data on Thursday, October 16th. The biotechnology company reported ($0.24) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pulmatrix stock. SBI Securities Co. Ltd. grew its position in Pulmatrix, Inc. (NASDAQ:PULM) by 15.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,565 shares of the biotechnology company’s stock after acquiring an additional 8,208 shares during the period. SBI Securities Co. Ltd.’s holdings in Pulmatrix were worth $418,000 at the end of the most recent quarter. 11.84% of the stock is currently owned by hedge funds and other institutional investors.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.